August 8, 2018—A new report by independent researchers refutes claims by the pharmaceutical industry that the 340B drug pricing program is so large it forces manufacturers to raise their prices. Writing in the Health Affairs Blog, a team of … [Read More...]
New Study on Cancer Care Has Important Implications for 340B
Print ArticleAugust 7, 2018—Critics of the 340B drug pricing program often claim that the lower cost of drugs for 340B hospitals is driving up the cost of care for cancer patients in hospital outpatient departments. But a new study published in the American Journal of Managed Care (AJMC) shows cancer care spending is actually lower […]
Faces of 340B: Care Close to Home
Print ArticleJuly 20, 2018 – The last thing that a cancer patient wants to do after receiving a chemotherapy treatment is to get in a car for a long drive home. But that’s exactly what some Nebraska patients would need to do if Johnson County Hospital weren’t able to provide that care locally. “The nearest […]
